Highlights
- EPS (TTM)
- -$1.02
- Total Revenue (TTM)
- $4.32M
- Gross Profit (TTM)
- $2.19M
- EBITDA (TTM)
- -$6.25M
- Year Range
- $2.52 - $12.37
- Target Price
- $15.00
- ROA (TTM)
- -32.20%
- ROE (TTM)
- -37.82%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Lipocine Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Lipocine Inc. (LPCN) has returned -0.50% so far this year and 151.26% over the past 12 months. Over the last ten years, LPCN has returned -26.87% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Lipocine Inc.
- 1D
- 5.41%
- 1M
- -19.78%
- YTD
- -0.50%
- 6M
- 180.35%
- 1Y
- 151.26%
- 3Y*
- 13.90%
- 5Y*
- -21.23%
- 10Y*
- -26.87%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Oct 22, 2013, LPCN's average daily return is +0.05%, while the average monthly return is +1.16%. At this rate, your investment would double in approximately 5.0 years.
Historically, 47% of months were positive and 53% were negative. The best month was Dec 2025 with a return of +133.4%, while the worst month was Nov 2019 at -83.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, LPCN closed higher 45% of trading days. The best single day was Feb 24, 2020 with a return of +67.0%, while the worst single day was Nov 11, 2019 at -70.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.08% | 10.67% | -19.78% | -0.50% | |||||||||
| 2025 | -11.48% | -28.94% | 3.58% | 4.09% | 2.11% | -6.51% | 2.22% | -9.91% | -2.06% | -6.67% | 29.32% | 133.43% | 64.55% |
| 2024 | 39.78% | -2.31% | 36.48% | -11.15% | 49.78% | 19.08% | -36.77% | -29.56% | 22.34% | 23.39% | -18.05% | 7.49% | 74.91% |
| 2023 | 33.23% | -14.85% | -29.51% | -18.26% | 4.75% | 8.86% | -1.39% | -20.52% | -24.56% | -14.43% | -5.49% | 15.77% | -58.74% |
| 2022 | 2.92% | 20.59% | 11.38% | -35.63% | -8.04% | -1.23% | -5.93% | -23.03% | -22.41% | -9.11% | 10.05% | -11.62% | -59.86% |
| 2021 | 30.15% | -10.17% | -5.03% | -6.62% | -13.48% | 14.75% | -5.71% | -0.76% | -16.79% | -4.59% | 5.77% | -9.90% | -27.13% |
Benchmark Metrics
Lipocine Inc. has an annualized alpha of 5.67%, beta of 0.67, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since October 23, 2013.
- This stock participated in 66.28% of S&P 500 Index downside but only -45.71% of its upside — more exposed to losses than it benefited from rallies.
- Beta of 0.67 may look defensive, but with R² of 0.02 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 5.67%
- Beta
- 0.67
- R²
- 0.02
- Upside Capture
- -45.71%
- Downside Capture
- 66.28%
Return for Risk
Risk / Return Rank
LPCN ranks 88 for risk / return — in the top 88% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Lipocine Inc. (LPCN) and compare them to a chosen benchmark (S&P 500 Index).
| LPCN | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.00 | 0.90 | +1.10 |
Sortino ratioReturn per unit of downside risk | 2.95 | 1.39 | +1.56 |
Omega ratioGain probability vs. loss probability | 1.35 | 1.21 | +0.14 |
Calmar ratioReturn relative to maximum drawdown | 3.92 | 1.40 | +2.53 |
Martin ratioReturn relative to average drawdown | 6.76 | 6.61 | +0.16 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore LPCN risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Lipocine Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Lipocine Inc. was 99.25%, occurring on Oct 30, 2023. The portfolio has not yet recovered.
The current Lipocine Inc. drawdown is 97.46%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.25% | Sep 9, 2015 | 2050 | Oct 30, 2023 | — | — | — |
| -60.5% | Nov 12, 2013 | 250 | Nov 7, 2014 | 171 | Jul 16, 2015 | 421 |
| -27.69% | Aug 12, 2015 | 9 | Aug 24, 2015 | 10 | Sep 8, 2015 | 19 |
| -10.96% | Jul 23, 2015 | 6 | Jul 30, 2015 | 7 | Aug 10, 2015 | 13 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Lipocine Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Lipocine Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LPCN relative to other companies in the Biotechnology industry. Currently, LPCN has a P/S ratio of 9.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |